Muenchener Rueck


Good 2020 results in COVID times, strong January renewals

25/02/21 -"• Net profit attributable to shareholders decreased by 56% to €1.21bn for 2020 but was in line with the revised company guidance • COVID-19-related losses were €3.5bn in FY2020 • The dividend ..."

Pages
53
Language
English
Published on
25/02/21
You may also be interested by these reports :
13/04/21
Our target price remains quite similar despite our valuation components being substantially adjusted. This reflects our medium-term optimism towards ...

09/04/21
Our new target price reflects our optimism for Mapfre. While the company has suffered from the COVID-19 crisis, accounting for the 7% paid dividend ...

07/04/21
Valuation wise takes a rest. That story was first released on 29-03. It has legs. Insurers were trashed on the eve of the COVID-19 pandemic on the ...

07/04/21
Our adjusted target price reflects our conservatism towards Sampo. While the company is benefiting from a stable and dominant position in the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO